Development Of DC-CTL And Study The Therapeutic Effects Of Different Routes In Ovarian Cancer Mice

OBJECTIVE Development of DC-CTL and study therapeutic effects of different routes in ovarian canert mice.BACKGROUND:Ovarian cancer is one of the three malignant tumors of the female reproductive system,nowadays still kills 80% of patients,the mortality rate ranks first in gynecological malignancies.The major issue with ovarian cancer is that it can spread inside the abdomen before causing symptoms.As the development of ovarian cancer has a very hidden features,more than 70% of patients find the ovarian cancer in very late stage and its five-year survival rate is less than 40%.As a silent killer,ovarian cancer has a poor prognosis.It is clear that new treatments are necessary for ovarian cancer.New treatments therefore have to be oriented differently.Now the advance treatment of ovarian cancer in clinical program is mainly the surgery combined with chemotherapy,But the side effects of such programs are on a larger scale,and also have a higher recurrence rate.New adjuvant therapy for cancer treatment is cancer immunotherapy.The clinical trials using immunotherapy have been performed for the treatment of variety of malignant tumors.A lot of research has shown CTL cytotoxic effect on ovarian cancer cells,But study did not explored the influence of injection route on therapeutic effect.This article will focus on the development of dendritic cell(DC)immunotherapy,their therapeutic effect,and analysis of different infusion ways.METHODS:To prepare DC-CTL cells from normal human peripheral blood,antigen-loaded DC group(group A1)and no antigen-loaded group(group A2).The cell killing effect of A1 and A2 on ovarian cancer cells was detected by enzyme-linked immunosorbent assay.To get 60 6-week-old female SPF mice in a clean bench,SKOV3 cells were inoculated subcutaneously into nude mice to establish cervical xenograft model.The model were established about 15 days.48 xenograft model mice were randomly divided into four groups,named subcutaneous injection group and the control group,tail-intravenous injection group and the control group.Two experimental groups mice were respectively injected by tail-subcutaneous injection and tail vein injection of 5 * 103 DC-CTL cell on day 21 and in the control group injected with the same volume of saline as a placebo.Mice were executed on day 35.The tumor tissue was weighed and separated statistically.RESULTS:Antigen-loaded DC-CTL cells had better killing effect on ovarian cancer cells.SKOV3 cells can make tumors about 15 days through injecting under the mice dorsal and neck skin.The tumor weight with the experimental group were significantly lower than those of the control group(P <0.05)and the tumor weight of tail-intravenous injection group was significantly lower than in mice by subcutaneous injection group(P<0.05).CONCLUSION:DC-CTL cells can effectively inhibit the development of mouse ovaries tumor.DC-CTL cells were injected into the tail vein of mice with ovarian cancer can have a significantly better therapeutic effect than subcutaneous injection in mice.The present results provide a certain basis for the clinical use of DC-CTL cells in ovarian cancer treatment options infusion.